



S/N 09/520,130

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ARATHOON ET AL. Examiner: A. HOLLERAN
Serial No.: 09/520,130 Group Art Unit: 1642
Filed: MARCH 7, 2000 Docket No.: 11669.132USC1
Confirmation No.: 1353 Customer No.: 23552
Title: A METHOD FOR MAKING MULTISPECIFIC ANTIBODIES
HAVING HETEROMULTIMERIC AND COMMON COMPONENTS

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 408488506 US
Date of Deposit: July 26, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450.

By: 
Name: Sheryl A. Boerboom

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

(37 C.F.R. § 1.97(c))

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Enclosed is a check in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

07/28/2004 EABUBAK1 00000119 09520130

02 FC:1806

180.00 0P

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: _____

July 16, 2004

Katherine M. Kowalchuk

Katherine M. Kowalchuk
Reg. No. 36,848
KMK:sab

23552

PATENT TRADEMARK OFFICE

FORM 149* OFFICE JUL 26 2004 PATENT & TRADEMARK OFFICE	INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 11669.132USC1	Application Number: 09/520,130
			Applicant: ARATHOON ET AL.	
			Filing Date: MARCH 7, 2000	Group Art Unit: 1642

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Luo, D. et al., "V1-Linker-Vh Orientation-Dependent Expression of Single Chain Fv Containing an Engineered Disulfide-Stabilized Bond in the Framework Regions", <u>J. Biochem.</u> , 118:825-831 (1995)
		Nieba, L. et al., "Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved <i>in vivo</i> folding and physical characterization of an engineered scFv fragment", <u>Protein Engineering</u> , 10(4):435-444 (1997)
		Reiter, Y. et al., "Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv", <u>Protein Engineering</u> , 7(5):697-704 (1994)

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	